Aminazine

Selected form

Chlorpromazine

Method of action: Antiemetic, Antipsychotic, Hypotensive, Psycholeptics

Treatment option: Autism, Meniere Disease, Hypomania, Dermatitis, Childhood Schizophrenia, Hiccups, Mania, Anxiety&Panic Attacks, Psychosis, Burping

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aminazine

Property	Description
Active ingredient	Chlorpromazine (Chlorpromazine Hydrochloride)
Pharmacological class	Neuroleptic (First-Generation Antipsychotic)
Origin	Synthetic
Primary Forms	Oral Tablet, Injectable Solution, Oral Liquid, Suppository
General Purpose	Central nervous system stabilization and severe antiemetic action

What is Aminazine and Its Pharmacological Class?

Aminazine is a synthetic psychotropic agent defined by its active ingredient, Chlorpromazine, a compound that pioneered its class. It is formally categorized as a neuroleptic drug belonging to the first-generation antipsychotic (FGA) class, making it a foundational treatment for central nervous system conditions. Chlorpromazine represents the prototypical compound within the phenothiazine antipsychotic family and is distinguished as a low-potency agent that works primarily by acting as a dopamine antagonist in the brain. This medication is utilized to manage severe agitation and thought disorders.

This synthetic compound, a substituted phenothiazine with the chemical formula C17H19ClN2S, was historically a critical advancement. Its early and widespread application established it as a benchmark neuroleptic against which newer agents were measured.

What is the General Therapeutic Purpose of Chlorpromazine?

The general purpose of Chlorpromazine is to provide stabilization of thought processes and severe agitation in patients experiencing chaotic mental states, alongside a powerful, secondary capability to control severe nausea. It functions as a multipurpose agent that simultaneously addresses central nervous system dysregulation and specific physical reflexes. For example, it is clinically recognized for its utility in situations requiring prompt, calming intervention.

Its clinical utility is driven by a dual action: stabilizing disrupted brain chemistry and forcefully suppressing the body's vomiting reflex. Chlorpromazine’s action is effective for controlling severe sickness, including that which is difficult to manage by other means. This dual therapeutic action allows the medication to offer relief from debilitating mental distress while also being effective in managing specific, persistent physical symptoms, such as intractable hiccups.

Available Forms and Core Composition

Aminazine is a single-ingredient product based on Chlorpromazine Hydrochloride and is manufactured in multiple dosage forms to suit varying clinical needs. These preparations include standard oral tablets and an oral liquid for routine administration, as well as injectable solutions for rapid delivery via intramuscular or intravenous routes. The drug is also available as a suppository for rectal administration, ensuring that patients who are unable to tolerate oral intake due to severe sickness can still receive the required medication.

Regulatory References

NCBI Bookshelf review

What side effects are possible with Aminazine?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Aminazine (Chlorpromazine), as detailed in government regulatory documents.

Adverse Reaction Scope

The safety profile is primarily characterized by effects on the Nervous System and Cardiovascular System. The frequency classification, based on regulatory standards, notes that Sedation (Somnolence) and Extrapyramidal Symptoms (such as Parkinsonism and acute Dystonias) are classified as Very Common or Common adverse reactions. Other frequently listed effects include Orthostatic Hypotension (low blood pressure upon standing) and Anticholinergic symptoms like Dry Mouth and Constipation.

Serious Adverse Reactions and Systemic Risks

Regulatory documents highlight several serious systemic risks, including potentially fatal conditions. These include Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening reaction. The drug is also associated with Tardive Dyskinesia, a potentially irreversible movement disorder linked to long-term use, and severe blood disorders such as Agranulocytosis. Furthermore, there is a risk of QT Interval Prolongation, which can lead to serious Ventricular Arrhythmias and sudden cardiac death.

Population- and Time-Related Safety

Safety constraints and patterns are noted for specific populations and durations of exposure. Older Adults are recognized as having increased susceptibility to effects like hypotension and sedation, and a specific warning exists regarding increased mortality risk in those with dementia-related psychosis. The risk of certain acute symptoms, such as dystonias, is more concentrated during treatment initiation, while the risk for Tardive Dyskinesia is associated with long-term exposure.

Aminazine is strictly contraindicated in patients with severe Central Nervous System depression, bone marrow depression, or severe liver damage.

Overdose and Emergency Response

Aminazine (Chlorpromazine) overdose is classified as a severe medical emergency associated with life-threatening outcomes and requires immediate professional intervention. The officially documented manifestations involve the Central Nervous System (CNS) and the Cardiovascular System.

CNS effects progress from initial somnolence and tremors to potentially life-threatening respiratory depression and coma. Other documented systemic signs include hypothermia and miosis. The cardiovascular risk is the principal life threat listed in regulatory sources, primarily involving profound hypotension leading to cardiovascular collapse. Overdose is formally linked to dangerous ventricular arrhythmias, including QT interval prolongation and Torsades de pointes.

The official labeling requires that individuals seek immediate medical attention upon suspicion of overdose. Emergency services must be contacted immediately if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Due to the high risk of serious and delayed effects, official protocols mandate hospitalization with continuous cardiac monitoring.

No specific antidote is known for Chlorpromazine overdose. Management is entirely focused on providing symptomatic and supportive treatment to maintain vital functions. A population-specific note in regulatory labeling is that elderly patients may be more susceptible to severe hypotensive effects during an overdose event.

Therapeutic Uses of Aminazine

What Aminazine Treats: Main Uses and Benefits

Aminazine (Chlorpromazine) is commonly used to help with symptoms across several therapeutic areas. This medication is primarily used to manage severe thought disorders, such as schizophrenia and the acute manic phase of bipolar disorder, and is applied in addressing nausea and vomiting.

This medication helps address clusters of symptoms like hallucinations, delusions, and profound agitation, providing important symptomatic relief that generally supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. It is also applied in therapeutic contexts where supportive relief is needed for highly persistent, disruptive physical symptoms, including severe or intractable nausea and vomiting and continuous, debilitating intractable hiccups (singultus).

It is relevant in clinical settings that involve acute or unstable symptom patterns. It is also used as an adjunctive therapy to moderate pronounced symptoms in specific, high-severity conditions like tetanus or acute porphyria. It assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive Management for Intractable Physical Symptoms Aminazine is commonly used to help with specific, highly resistant physical symptoms, such as uncontrolled vomiting and persistent diaphragmatic spasms (hiccups), when symptoms are difficult to manage.

Regulatory References

National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Absolute Contraindications (Non-Eligibility)

Aminazine (Chlorpromazine) is contraindicated and must not be used in specific, high-risk patient populations as defined by regulatory bodies. This exclusion applies to individuals in comatose states or those with severe Central Nervous System (CNS) depression. Use is also strictly prohibited in patients with circulatory collapse, bone marrow depression, or a known hypersensitivity to chlorpromazine or other phenothiazine medications. Certain tablet formulations are contraindicated in patients with conditions like congenital galactosemia.

Restrictions by Age and Comorbidity

Eligibility is constrained by age. The medication is generally not established for use in children under 6 months of age. A significant restriction exists for older adults: the drug is not approved for the treatment of dementia-related psychosis, a use associated with an increased risk of death according to regulatory warnings.

Patients with severe liver or renal failure require close monitoring due to the risk of drug accumulation. Conditions such as cardiovascular disease and epilepsy necessitate extreme caution.

Pregnancy and Lactation Status

Regulatory documents state that use during pregnancy is not recommended/avoided unless essential. Furthermore, the drug is typically contraindicated or not recommended for nursing mothers due to its excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail clinically significant constraints regarding the co-administration of Aminazine (chlorpromazine) with various medicinal products and substances. These constraints are structured around the risks of pharmacodynamic enhancement (additive effects) and pharmacokinetic interference (changes in drug exposure).

Interaction Classifications

Classification	Interacting Product Category	Primary Regulatory Constraint
Contraindicated	Dopaminergics (e.g., quinagolide, cabergoline)	Risk of reciprocal pharmacological antagonism.
Contraindicated	Specific Antidepressants (e.g., Citalopram, Escitalopram)	Risk of serious adverse reactions, often related to cardiac effects.
Caution/Monitoring Required	CNS Depressants (e.g., alcohol, strong analgesics, hypnotics)	Risk of increased Central Nervous System depression.
Caution/Monitoring Required	QT-Prolonging Agents (e.g., quinidine, sotalol)	Risk of additive prolongation of the cardiac QT interval.

Mechanism of Action

Antagonism of Dopaminergic Pathways for Central Modulation

Aminazine's mechanism centers on the antagonism of multiple central nervous system receptors, prominently including the Dopamine receptors (D2) in the mesolimbic pathway. This blockade modulates hyperactive dopaminergic signaling, which results in a reduction of central neural output and contributes to the drug's overall modification of signal transduction.

️ Multi-Receptor Blockade for Emetic Pathway Inhibition

The medication strongly engages receptors beyond dopamine, including Histamine ( H1) and Muscarinic ( M1) receptors in the Chemoreceptor Trigger Zone (CTZ) of the brainstem. This combined multi-receptor blockade suppresses the signals that initiate the emetic reflex, resulting in functional inhibition of the vomiting response.

Peripheral and Autonomic System Modulation

The mechanism also involves the antagonism of Alpha-Adrenergic receptors (alpha1) found both centrally and on peripheral blood vessels. The disruption of alpha1-mediated signaling can modulate vascular tone, potentially leading to postural blood pressure changes, while H1 antagonism contributes to generalized sedative consequences. This mechanism, predominantly driven by D2 antagonism, exhibits a lower modulatory effect on processes linked to cognition or motivation, which are primarily mediated by other neurotransmitter systems and pathways.

Dosage and Administration Information

Aminazine (Chlorpromazine) is administered via oral (tablet, liquid concentrate), intramuscular (IM) injection, or intravenous (IV) injection. The protocol begins with a low starting dose followed by a gradual titration phase using divided doses (e.g., three or four times daily) until an effective maintenance level is achieved. The typical adult daily dose for stabilization is around 400 mg, though the total dose rarely exceeds 1000 mg per day for extended periods.

For prompt control of severe symptoms, initial treatment may be administered as a 25 mg IM injection, with subsequent 25 mg to 50 mg injections permissible in one hour if necessary. Oral tablets should be taken with food or a full glass of water or milk to help mitigate gastric irritation. The oral concentrate requires dilution with a beverage immediately before administration.

Specific procedural constraints include the requirement that the patient remain recumbent (lying down) for at least 30 minutes following any parenteral administration. Dosing is adjusted based on population: older adults generally require a lower starting dose (often one-third to one-half the usual adult dose) and a more gradual increase in dosage. Pediatric patients (ages 6 months and older) are dosed according to body weight. Once stability is achieved, any cessation of the medicine mandates that the dose be gradually tapered over time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aminazine

Evidence for Use in Severe Thought Disorders and Schizophrenia

Aminazine, known by its active ingredient Chlorpromazine, has been studied for the management of conditions like schizophrenia using older, often short-term Randomized Controlled Trials (RCTs). These studies monitored adult populations experiencing either acute episodes or chronic symptoms, comparing the drug to placebo or other medications. Findings from systematic reviews indicate patterns where a lower frequency of measured symptom return (relapse) was observed in some study groups compared to those receiving placebo over medium-term periods (e.g., up to two years). Comparative evidence for Aminazine against newer agents is often lacking, and many foundational trials had modest sample sizes to fully assess differences in measured outcomes.

Evidence for Use in Acute Manic Episodes, Nausea, and Intractable Hiccups

Aminazine was evaluated in short-term clinical trials for the acute manic phase of bipolar disorder, with researchers exploring whether its use alongside established mood stabilizers was associated with particular patterns of symptom change during an episode. For severe nausea and intractable hiccups, the evidence is primarily historical, derived from clinical trials and case reports that examined the cessation of acute episodes. For intractable hiccups, research confirms that evidence is limited to older observational data.

Limitations and Research Gaps

Most available randomized evidence was observed in general adult populations. Long-term outcomes are not well characterized, and evidence is limited regarding functional ability or symptom intensity changes over many years of continuous use. Data for special groups like children or older adults remain insufficient. The overall evidence quality for core outcomes is often rated as very low certainty, reflecting the reliance on older, heterogeneous trial data that often had limited follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Aminazine (FAQ)

Q: How quickly does Aminazine start to affect a person?

The time it takes for effects to begin can depend on the form of the medicine and the condition being addressed. Official product information indicates that for symptoms like severe nausea and vomiting, the onset of action may be rapid. When treating psychotic symptoms, some clinical improvement can be seen within about a week, though it can take several weeks or longer to reach the maximum effect on behavior.

Q: How long does the effect of one Aminazine dose typically last?

Pharmacology data indicates that the time it takes for the body to eliminate half of the drug (known as the elimination half-life) is reported to be approximately 30 hours. This measurement describes how long the medication is likely to be present in the body after a single dose.

Q: Can Aminazine cause weight gain?

Yes, official regulatory documents list weight gain as a potential side effect associated with the use of this medication. Patients using this drug are sometimes monitored for changes in weight over the course of treatment.

Q: Can older adults safely use Aminazine?

Official guidance notes that older adults often require lower dosages, and close monitoring is described in regulatory documents, as they may be more susceptible to certain effects like low blood pressure and involuntary muscle reactions. Regulatory warnings also state that use is not approved for patients with dementia-related psychosis.

Q: Is Aminazine approved for use in children?

According to official regulatory information, this medication is approved for the management of severe behavioral problems and excessive motor activity in children aged 6 months and older. Use is not established for children younger than 6 months.

Q: What is a potential long-term effect of taking Aminazine?

A key concern associated with long-term exposure to this class of medication is the development of Tardive Dyskinesia (TD). This is a potentially irreversible movement disorder for which periodic monitoring is described as necessary throughout treatment.

Q: Why do some people feel restless after taking Aminazine?

Feeling restless is a type of side effect known as an Extrapyramidal Symptom, which includes involuntary movement issues. These effects are related to the drug's primary mechanism of action: blocking dopamine D2 receptors in the brain.

Q: What is the expected long-term use duration for Aminazine?

Official guidance suggests that following a first episode of psychosis, treatment may be continued for at least one year. For subsequent episodes, the need for long-term treatment may be indefinite, and periodic re-evaluation of the dosage is generally advised in clinical guidelines.

Q: Can Aminazine make you more sensitive to the sun?

Yes, regulatory documents list photosensitivity as a potential side effect. This means individuals using the drug may be unusually sensitive to light, increasing the risk of sunburn or rash.

Q: Does using Aminazine require any specific lab tests?

Official guidance indicates that monitoring is necessary throughout treatment. This may include checking vital signs like blood pressure and weight, and certain lab work, such as blood cell counts, glucose, and lipids.

Q: How does Aminazine influence dopamine levels?

The drug is known to influence the signaling of the neurotransmitter dopamine by acting as an antagonist (or blocker) at dopamine D2 receptors in the brain. This action modulates the transmission of signals, rather than directly changing the overall amount of dopamine produced.

Q: Does Aminazine help with anxiety?

Official regulatory documents list the use of this medicine for the relief of apprehension and restlessness before surgery (preoperative sedation). However, it is not generally indicated or approved for the routine management of generalized anxiety disorder.

Q: What is the difference between Aminazine and Prolixin?

Aminazine (Chlorpromazine) and Prolixin (Fluphenazine) both belong to the phenothiazine class of antipsychotic medications. A distinction is their potency: Aminazine is generally considered a low-potency agent, while Fluphenazine is classified as a high-potency agent.

Q: Are there any foods or drinks to avoid while taking Aminazine?

Official product information states that the oral concentrate form should not be mixed with nutritional supplements or enteral (tube) feedings. This specific interaction is noted because mixing the concentrate with these products may reduce its beneficial effect.

Q: Does Aminazine interact with common pain relievers?

Official warnings specifically detail a major interaction risk when this medicine is used alongside narcotic or opioid pain medications. This is due to the potential for the drugs to have an additive depressant effect on the Central Nervous System and breathing.

Q: Is it safe to drive or operate machinery while using Aminazine?

Regulatory safety warnings advise caution when performing activities that require full mental and physical alertness, such as driving or operating heavy machinery. This is especially true during the initial days of treatment when the sedative effects may be strongest.

Q: Are there any known interactions between Aminazine and herbal supplements?

Official information specifically warns against co-administration with Cannabis due to the risk of additive Central Nervous System depression. General guidance on other herbal products is not uniformly documented in core labels.

Q: Why is Aminazine sometimes used before surgery?

Regulatory labeling lists one of the drug's approved uses as providing preoperative sedation. This means the medicine is used to help relieve restlessness and apprehension in a patient before they undergo an operation.

Q: Do you need a special prescription to get Aminazine?

This medicine is categorized as a prescription-only drug, which is available only with authorization from a licensed provider. In the United States, it is also categorized as not a controlled substance.

Q: Is it possible to have an allergic reaction to Aminazine?

Yes, official documents note that an allergic reaction or hypersensitivity to the drug is possible. Certain severe reactions, including serious skin disorders, are listed as potential adverse effects in regulatory warnings.

How should Aminazine be stored and disposed of?

Storage and Disposal Requirements for Aminazine (Chlorpromazine)

The official storage and disposal guidelines for Aminazine are defined by regulatory labeling to maintain drug stability and ensure safety.

Requirement	Official Instructions
Temperature	Store at controlled room temperature, ideally between 15 C and 30 C, and avoid temperatures above 40 C.
Protection	Medication must be protected from light, excess heat, and moisture. Liquid forms should not be frozen, as this may compromise the product.
Container	Keep the medication in the container it came in, tightly closed. Liquid concentrates are often dispensed in amber glass to protect against light.
Child Safety	Always keep Aminazine products out of the reach of children and use child-resistant packaging.
Disposal	Do not dispose of Aminazine in household trash or pour it down a sink or toilet. Utilize a drug take-back program or follow official guidance for disposal, such as mixing with an undesirable substance and sealing it before discarding.